Skip to main content
2024 CNSF Congress Main banner
Neuro|News Annual Edition
Final Program


Calendar-of-Events
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation

Industry Supported Session

Lunch 'n Learn: Amyloidosis - A Neuropathy You can't Afford To Miss! Distinguishing Amyloid Neuropathy from CIDP and Others

Tuesday, May 21, 2024
12:00 PM – 1:30 PM EST
Location:MM: Tudor 7 & 8

Audience:

Adult Neurologist, Neurophysiologist, Resident, Fellow, Nurses with interest in topic

Learning Level:

Basic (Resident, New Information), Intermediate (Practicing Physician)

Learning Format:

Audience response system (interactive presentation), Case studies, Discussion group/peer exchange/user groups (use of some technology for live engagement), Forum/panels (will include a Q&A with a cardiologist), Lecture/plenary method

CanMEDs Roles:

Medical Expert, Scholar, Communicator, Collaborator, Leader, Health Advocate, Professional

This session is a multi-disciplinary audience interactive case-based program that will provide an overview of the ATTR amyloidosis disease spectrum, and discuss the diagnosis, treatment, and management of patients with ATTR. The session will help the audience understand the challenges related to the diagnosis and treatment of ATTR amyloidosis, and will provide fundamental knowledge of current and emerging therapeutic approaches.

This event, chaired by Dr. Michelle Mezei (Division of Neurology, University of British Columbia), will highlight the importance of a multi-disciplinary approach to the management of ATTR patients, and will include Dr. Sami Khella (Department of Neurology, University of Pennsylvania) and Dr. Deigo Delgado (Division of Cardiology, University of Toronto) to facilitate a comprehensive and multi-disciplinary discussion. Through a case-based approach, the panel will provide their perspective and discuss the importance of collaboration between neurologists and cardiologists in the management of ATTR amyloidosis.

This program was developed by the CNSF and AstraZeneca and was planned to achieve scientific integrity, objectivity and balance. It is an unaccredited learning activity and not eligible for MOC credits.

Learning Objectives:

  • Understand the prevalence, heterogenicity, and burden of ATTR-amyloidosis
  • Discuss challenges related to the diagnosis of ATTR amyloidosis
  • Compare existing and emerging therapeutic options for the treatment of ATTR amyloidosis
  • Evaluate the importance of a holistic and multidisciplinary approach to ATTR amyloidosis patient care

Presentations:

  • 12:00 PM – 12:20 PM EST
    Navigating the Landscape of ATTR Amyloidosis

    Faculty: Sami Khella

  • 12:20 PM – 12:40 PM EST
    Interactive case study ATTR with PN

    Faculty: Sami Khella

  • 12:40 PM – 1:00 PM EST
    Interactive case study ATTR with PN/CM

    Faculty: Diego Delgado

  • 1:00 PM – 1:15 PM EST
    Q&A

    Faculty: Michelle Mezei